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INTRODUCTION
This publication contains recommendations regarding 
terminology, diagnostics, and treatment of cervical squamous 
intraepithelial lesions. It was composed in cooperation with 
the Section of Cervix Pathology, Colposcopy, and Cytology 
of the Polish Gynecological Society and the Polish Society 
of Colposcopy and Cervix Pathophysiology, and the Polish 
Society of Pathologists. The objectives of this publication are: 
 Ū clarification of terminology of cervical squamous in-
traepithelial lesion (SIL);
 Ū determination of biomarkers useful for interpretation 
of unclear microscopic morphology changes requiring 
further differentiation between a high grade squamous 
intraepithelial lesion (HIL), which is considered a precan-
cerous condition, and changes that are considered nega-
tive for an intraepithelial lesion or malignancy (NILM);
 Ū determination of clinical guidelines for management 
of cervical SIL;
 Ū promulgation of guidelines, improving communication 
between pathologists, as well as clinical professionals 
and contributing to more precise and effective diag-
nostics and therapy of patients with a precancerous 
condition of the cervix. 
TERMINOLOGY REGARDING SIL
The World Health Organization (WHO) in 1975 proposed 
unification of terminology used in histopathological reports 
regarding squamous-cell carcinoma precursor lesions. The 
term “dysplasia” referred to replacement of normal cells of 
squamous stratified epithelium with abnormal, dysplastic 
cells spreading onto the consecutive layers of epithelium. 
Depending on how many layers were affected, dysplasia was 
classified into three grades: mild, moderate and severe. The 
WHO defined dysplasia as carcinoma in-situ affecting the 
entire or almost entire thickness of the epithelium. At pre-
sent, the concept that separates dysplasia from carcinoma 
in-situ in a classification system is criticized. It is commonly 
known that both changes represent the same process, and 
they directly transform from one into the other. 
In 1980, the International Society of Gynecological Patholo-
gists (ISGP) changed the term “dysplasia” into “cervical intraepi-
thelial neoplasia” (CIN) and erased the category “carcinoma 
in-situ”. A conclusion was reached that preinvasive lesions in 
the epithelium are a constant series of events transforming 
from one into the other. The term “CIN” was divided into three 
sub-stages: CIN I, CIN II, CIN III; depending on the level of 
dysplasia evident. The preinvasive cancer was included in the 
CIN II category. The aforementioned classification was pro-
gressive because it also considered precursor lesions in strati-
fied squamous epithelium as a process of carcinogenesis. It 
was also noted that CIN I is not entirely a precancerous lesion, 
because it can regress even without treatment.
Cytologic reporting based on the Bethesda System 
(TBS) was elaborated and implemented into diagnostics in 
1988 (modifications were presented in 1991 and 2001). This 
report explained the terminology of lesions suspected of 
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cancer and CIN based on abnormal morphology of the cells 
derived from stratified squamous epithelium and glandular 
epithelium of the cervix. 
Cytologic reporting based on the Bethesda System (TBS) 
was implemented in 2001. The rules of aforementioned 
classification are presented in Table 1.
In 2012, the College of American Pathologists (CAP) and 
American Society of Colposcopy and Cervical Pathology (AS-
CCP) elaborated the Lower Anogenital Squamous Terminology 
(LAST) regarding changes caused by the Human Papillomavi-
rus (HPV). The lower anogenital region is an area covered by 
mucous membrane or skin within the cervix, vagina, vulva, 
penis, and crotch, including the anal canal and perianal region. 
The cells of nonkeratinized stratified squamous epithelium, 
mucous membrane or keratinized epithelium of the skin are 
vulnerable to HPV infection. Genotypes of HPV were assigned 
into two groups depending on the risk for malignant transfor-
mation. The HPV subtypes of low oncogenic potential: 6, 11, 42, 
43, 44, and 53 are related to moderate intraepithelial neoplasia 
and papillary epithelial lesions resembling genital and plain 
warts. Whereas infections associated with moderate and high 
risk for neoplastic changes are caused by the HPV genotypes 
of high oncogenic potential (types: 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, and 68). HPV 16 and HPV 18 type usually 
coexist with HSIL and squamous invasive cancer of the cervix.
Recommendations of the WHO and AP/ASCCP suggest 
that histopathological reports describing changes in tissue 
samples should be written using the terminology based on 
the two-stage Bethesda System, as in reports from gyneco-
logical cytology. According to the recommendations of 
WHO/ASCCP Intraepithelial Lesion /IN are classified as: Low 
Grade Squamous Epithelial Lesion (LSIL), Mild Dysplasia (CIN I) 
High Squamous Epithelial Lesion (HSIL), Moderate Dysplasia 
(CIN II), and Severe Dysplasia (CIN III).
Genital warts, which were not previously classified as 
CIN, were added to the LSIL group, and CIN II and CIN III 
were classified into one category - HSIL. In practice, CIN and 
SIL are often associated together and defined as LSIL (CIN I), 
HSIL (CIN II) or HSIL (CIN III). Comparison of terminology 
used in histopathological reports according to different 
classification systems for cervical preinvasive squamous 
lesions are presented in Table 2. 
SUMMARY.  
RECOMMENDATIONS FOR DESCRIPTION  
OF THE TYPE OF SIL
It is recommended to use unified histopathological 
terminology for description of anogenital lesions caused 
by HPV. 
It is recommended to use two-stage terminology for 
description of changes in morphology of intraepithelial 
neoplasia (IN) of the anogenital region caused by HPV 
such as low-grade squamous intraepithelial lesion (LSIL) 
and high-grade squamous intraepithelial lesion (HSIL). 
Table 1. Bethesda System terminology of 2001
Abnormal stratified squamous epithelium
ASC-US Atypical cells of stratified squamous epithelium of unspecified characteristics
ASC-H Atypical cells of stratified squamous epithelium, high-grade squamous intraepithelial lesion (HSIL) cannot be excluded
LSIL Mild intraepithelial neoplasia; concerns HPV infections/low-grade dysplasia CIN I
HSIL High grade squamous intraepithelial lesion; Including moderate (CIN II) and severe neoplasia (CIN III), CIS (carcinoma in situ)
Squamous carcinoma In case of suspected invasion
Abnormal cells of glandular epithelium
AGC Atypical cells of the cervical glandular epithelium (AGC) qq or uterine body, or other granular
AIS Cervical adenocarcinoma in situ
Adenocarcinoma Cells of adenocarcinoma of the cervix, uterine body or an extrauterine tumor
Table 2. Comparison of the CIN and SIL classification systems for cervical precancerous lesions
Former diagnosis dysplasia CIN classification “cervical intraepithelial neoplasia”
Bethesda system, SIL
“squamous epithelial lesion”
Papilloma Papilloma LSIL 
Mild dysplasia CIN I LSIL 
Moderate dysplasia CIN II HSIL 
Severe dysplasia CIN III HSIL 
Preinvasive carcinoma CIN III HSIL 
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RULES FOR CONDUCTING CERVICAL 
CYTOLOGY SCREENING
Necessary data for evaluation of cervical 
cytology screening
The vast majority of cytologic smears sampled for cer-
vical cancer screening are normal and do not present with 
abnormalities in the cells of stratified squamous epithelium 
and glandular epithelium. While formulating the diagnosis, 
the cytologic presentation should be evaluated in the con-
text of women’s age and phase of menstruation cycle. In 
young women, there are mostly mature cells of the stratified 
squamous epithelium in the cytologic smears due to the ef-
fect of estrogens. Cytologic smears obtained from pregnant 
women contain mostly intermediate glycogen-rich cells 
(fusiform cells), as the result of progesterone. Cytologic 
smears in women after menopause contain mostly basilar 
and peribasilar cells due to a lack of estrogens. In abnormal 
and atypical cells as well as in intraepithelial neoplasia, 
pleomorphism occurs, and the proportion of the nucleus 
increases relative to the cytoplasm. The silhouette of the 
nucleus is irregular, the nuclear membrane is thin, and there 
are protrusions and vacuoles inside the nucleus. The nu-
cleoli are clearly visible with abnormal figures of division. 
The stage of these changes in the cell determines whether 
atypia or intraepithelial cervical neoplasia should be diag-
nosed. Koilocytes are a key cytologic sign of HPV infection. 
A koilocyte is an abnormal squamous epithelial cell with 
enlarged, hyperchromatic nucleus surrounded by large, 
clear space with peripheral cytoplasm. 
The algorithm for managing cytologic specimens 
obtained from the cervix
A smear obtained from the squamocolumnar junc-
tion and cervical canal with a brush must be immediately 
placed onto the glass and preserved with fixatives de-
signed for that purpose (in case of conventional cytology) 
or placed into a specially dedicated container with a liquid 
base (in the case of liquid-based cytology). The watch glass 
with the smear or the container with the probed material 
on the liquid medium should be labeled. The labelling 
should contain the diagnostic test number and name of 
the patient. A referral with the patient’s name, personal 
ID number and/or bar code should be attached to the 
smear or container. Information about the patient’s last 
menstrual period and potential hormone therapy should 
be mentioned on the referral.
It is recommended that cytologic smears are performed 
using the Papanicolaou (PAP smear). Diagnostic test results 
should be presented according to Bethesda’s classification. 
In cases when the result of the cytologic evaluation is nor-
mal, biomarker tests are not recommended. 
BIOMARKERS USED IN CERVICAL 
INTRAEPITHELIAL NEOPLASIA
Biomarkers used in cytologic smears 
Cytologic diagnosis of ASC-US or LSIL indicates the 
presence of abnormal stratified squamous cells. Such mor-
phological changes in the cells may be a manifestation of 
an inflammatory process or their early transition to a precan-
cerous state after the initiation of carcinogenesis. In these 
cases differentiation between benign lesions that do not 
require treatment and actual precancerous changes one of 
which is HSIL, do require management. Differential diagno-
sis of these lesions may be performed with a two-colour im-
munohistochemical test with simultaneous use of p16 and 
Ki67 antibodies, which are included in the CinTecPlus test 
kit. When the process of malignant transformation in cervical 
epithelial cells is initiated, expression of p16 and Ki67 pro-
teins is elevated. In such clinical cases, the CinTecPlus test 
helps select those patients with an abnormal cytologic eval-
uation, who require further diagnostics. The CinTecPlus 
test can be considered positive when the nucleus of the 
epithelial cell is stained red (Ki 67 protein expression) and 
the cytoplasm brown (p16 protein expression). A test con-
taining both biomarkers p16/Ki-67 in one set provides a high 
sensitivity and specificity in detecting actual precancerous 
lesions and cervical cancer. The ability to perform this test 
on smears significantly increases the quality and precision 
of the diagnosis by decreasing the number of false positive 
and false negative results. Our experiences in Poland show 
a high accuracy of this test, which in the case of diagnosing 
ASC-US amounts to 41%, LSIL — 56% and HSIL — 73%. 
Biomarkers in diagnostics of  
HPV-dependent lesions of the anogenital area
Histological examination of samples taken under the 
colposcope from lesions suspected to be precancerous or 
cancerous is the next step in diagnostics after an abnormal cy-
tologic evaluation result. The p16 protein is a useful biomarker 
that provides additional information to microscopic evalua-
tion and confirms the diagnosis. The immunohistochemical 
examination using p16 antibodies helps eliminate or confirm 
the neoplastic transformation of squamous epithelial cells in 
the cervix. In normal epithelial cells, there is no p16 expres-
sion, or its level is low. P1 protein expression is significantly 
elevated in epithelial cells in which HPV virus genotypes with 
a high oncogenic potential initiated the oncogenic transfor-
mation and led to their transition into precancerous lesions 
or cervical cancer. The ability to interpret the immunohisto-
chemical reaction with the use of the p16 antibody by the 
pathomorphologist is crucial for the accuracy and credibility 
of this test. A clearly pronounced and extensive color reaction 
with the p16 antibody confirms the lesion to be precancer-
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ous. Non-uniform colouration of the epithelial cells excludes 
the diagnosis of a neoplastic process.
SUMMARY.  
RECOMMENDED CLINICAL GUIDELINES
A positive result of the immunocytochemical test 
with p16 and Ki-67 antibodies (CinTecPlus) conducted 
when in case of unclear results of ASC-US cytologic 
classification suggests the diagnosis of LSIL (eventually 
ASC-H*) and is an indication for more extensive cervical 
cancer diagnostics (Fig. 1). The extensive diagnostic pro-
cess includes a colposcopy and, if necessary, sampling 
the most suspicious lesions and endocervical curettage. 
High expression combined with a multicellular colour 
reaction for p16 indicates an on-going carcinogenic 
process and suggests that a specialist in cytodiagnos-
tics underestimated morphological changes present in 
cytologic smears. This may result in omitting medium 
* Cytologic diagnosis of ASC-H is an indication for extended diagnostics 
— colposcopy. The results of an immunohistochemical complemen-
tary p16/Ki67 test may prove helpful
or high-grade neoplasia (HG SIL). The identification of 
advanced epithelial lesions under a colposcope is neces-
sary for selective biopsy. Final histopathological diagno-
sis confirming the presence of HSIL type lesions (CIN II 
and/or CIN III) is an indication for excision with a margin 
of healthy tissue. In cases where the lesion was not iden-
tified under colposcope or high-grade intraepithelial 
lesion was not detected in the biopsy sample obtained 
from a p16/k67 positive patient, the patient should re-
main under strict cytologic and colposcopic observation 
supported with virological testing. A cytologic smear 
should be performed after 3-6 months complemented 
by a “wide” test covering at least 14 HPV genotypes (DNA 
HPV HR). A normal result of the cytologic smear obtained 
in two follow-up tests performed with a 3–6 month in-
terval and a negative result of one test for DNA HPV HR 
enables the physician to refer the patient for a routine 
cytologic screening. An abnormal result of a cytologic 
evaluation and/or a positive DNA HPV HR test result is 
a ground for repeating a colposcopy in order to identify 
neoplastic lesions or qualify the patient to a high-risk 
group.
Figure 1. The algorithm for abnormal cytologic result with immunocytodetection of p16/Ki67 proteins
ASC-US
LSIL
Colposcopy
(accepted)
P16/Ki67
(recommended)
Positive Negative
Colposcopy
Endocervical curettage
PAP smear
in 3–6 months
DNA HPV HR test 
(recommended)
DNA HPV(-) DNA HPV(+)
PAP smear
in 6 months
Colposcopy
No changes CIN2 and/or CIN3
PAP(-)
DNA HPV(-)
PAP ≥ ASC-UC
and/or
DNA HPV HR(+)
Routine
screening
Normal colposcopy
ndings
CIN2 and or CIN3 
— treatment
No changes 
— qualication to risk group 
— PAP smear every 6 months
PAP smear 
+ DNA HPV test 
in 3–6 months
Treatment
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CAP/ASCCP RECOMMENDATIONS  
FOR USING P16 AS A BIOMARKER  
OF PRECANCEROUS LESIONS IN CERVICAL SAMPLES
Recommendation 1
The most important diagnostic element of cervical precancerous lesions includes distinguishing actual precancerous 
changes such as HSIL from morphological changes imitating HSIL described as “Negative for Intraepithelial lesion or malig-
nancy” (NILM). The following morphological images fall into this category: early squamous metaplasia, atrophic changes 
in the epithelium, repair, and regeneration after inflammation. A negative test for p16 enables a NILM diagnosis, whereas 
a positive p16 test corresponds with HSIL (Fig. 2).
HSIL HSIL-RESEMBLING
LESION
P16 STAINING 
NEGATIVE
P16 STAINING
POSITIVE
NO HSIL HSIL
P16 STAINING
BIOPSY
RECOMMENDATION 1
vs.
Figure 2. The algorithm for differentiation of HSIL and NILM with 
histological examination using the p16 biomarker
 
Recommendation 2
Changes in pap smears recognized in hematoxylin and eosin staining as HSIL (CIN II) classified between LSIL or changes 
associated with infection with no HPV etiology, not about actual changes HSIL requires p16 staining applications. A negative 
result of p16 staining indicates the presence of LSIL OR NILM and a change not related to HPV infection , while strong and 
poured reaction with p16 corresponds to the change of a HSIL (Fig. 3)
MORPHOLOGICAL HSIL (CIN II)
P16 STAINING 
NEGATIVE
P16 STAINING 
POSITIVE
LSIL OR CHANGE
NOT RELATED TO
HPV INFECTION
HSIL
P16 STAINING
BIOPSY
RECOMMENDATION 2
Figure 3. The algorithm for histological differentiation between HSIL 
(CIN II) with real premalignant conditions (e.g. HSIL)
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Recommendation 3
Immunohistochemical testing for p16 is also useful for differentiation between LSIL and HSIL in case of any inconsist-
ency in opinions of the specialists regarding assessment of the samples obtained from the cervix in haematoxylin and eosin 
staining (Fig. 4).
Figure 4. The algorithm for diagnostic inconsistency between 
specialists in pathology after diagnosing LSIL and HSIL
PROFESSIONAL INCONSISTENCY:
DIFFERENTIAL DIAGNOSTICS
BETWEEN CHANGES OF HSIL
AND LSIL MORPHOLOGY
P16 STAINING P16 STAINING
LSIL HSIL
P16 STAINING
BIOPSY
RECOMMENDATION 3
 
Recommendation 4 
Immunohistochemical staining p16 is not recommended as a routine diagnostic test for lesions that present with clear 
morphology of either HSIL (CIN II) or LSIL (Fig. 5).
MORPHOLOGICALLY
CONFIRMED HSIL (CIN III) or LSIL
 LSIL OR
HSIL (CIN III)
P16 STAINING
BIOPSY
RECOMMENDATION 4
Figure 5. The diagnostic algorithm when the histological diagnosis  
of LSIL and HSIL is clear in haematoxylin and eosin staining
 
Recommendation 5 
It is recommended to perform immunohistochemical testing for p16 in patients with a cervical lesion less advanced 
than LSIL, in whom previous cytologic evaluation detected HSIL, ASC-H, ASC-US/HPV16 or AGC. A negative result for 
p16 testing indicates the presence of LSIL or a lesion induced by HPV infection whereas a positive p16 reaction corresponds 
with HSIL. Immunohistochemical expression of p16 also confirms cervical adenocarcinoma in situ (AGC).
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SUMMARY.  
RECOMMENDATIONS FOR USING  
THE P16 BIOMARKER  
FOR HISTOPATHOLOGICAL EXAMINATION  
OF SPECIMENS OBTAINED FROM THE CERVIX
1. The result of immunohistochemical reaction for 
p16 should be interpreted as a supplement for his-
topathological analysis of the specimen stained with 
haematoxylin and eosin.
2. Strong, homogeneous and spread colour reaction is 
interpreted as a positive result of p16.
3. A negative result of p16 testing eventually enables 
the diagnosis of lesions such as NILM, LSIL and lesions 
unrelated with HPV infection.
4. A positive result of p16 should be interpreted as HSIL.
5. Every positive result of p16 in the immunohisto-
chemical reaction requires further diagnostics such 
as colposcopy and diagnostic abrasion.
Conflict of interest
The authors declare that there is no conflict of interest in 
the presented recommendations.
REFERENCES
1. Benevolo M, Mottolese M, Marandino F, [et al.]. Immunohistochemical 
expression of p16(INK4a) is predictive of HR-HPV infection in cervical 
low-grade lesions. Mod Pathol. 2006,19, 384–391. 
2. Benevolo M, Terrenato I, Mottolese M, [et al.]. Comparative evaluation 
of nm23 and p16 expression as biomarkers of high-risk human papillo-
mavirus infection and cervical intraepithelial neoplasia 2(+) lesions of 
the uterine cervix. Histopathology 2010, 57, 580–586.
3. Bergeron C, Ordi J, Schmidt D, Trunk MJ, Keller T, Ridder R. Conjunctive 
p16INK4a testing significantly increases accuracy in diagnosing high-
-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2010, 133, 
395–406. 
4. Darragh TM, Colgan TJ, Cox JT, [et al.]. The Lower Anogenital Squamo-
us Terminology Standardization Project for HPV-Associated Lesions: 
Background and Consensus Recommendations from the College of 
American Pathologists and the American Society for Colposcopy and 
Cervical Pathology. Arch Pathol Lab Med. 2012, 136, 1266–1297.
5. Del Pino M, Garcia S, Fuste V, [et al.]. Value of p16(INK4a) as a marker of 
progression/regression in cervical intraepithelial neoplasia grade 1. Am 
J Obstet Gynecol. 2009, 201, 88.e1–7. 
6. Horn LC, Reichert A, Oster A, [et al.]. Immunostaining for p16INK4a used as 
a conjunctive tool improves interobserver agreement of the histologic 
diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2008, 
32, 502–512. 
7. Klaes R, Benner A, Friedrich T, [et al.]. p16INK4a immunohistochemistry 
improves interobserver agreement in the diagnosis of cervical intraepi-
thelial neoplasia. Am J Surg Pathol. 2002, 26, 1389–1399. 
8. Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds).WHO Clas-
sification of Tumors of Female Reproductive Organs. IARC Lyon 2014.
9. Negri G, Vittadello F, Romano F, [et al.]. p16INK4a expression and pro-
gression risk of low-grade intraepithelial neoplasia of the cervix uteri. 
Virchows Arch. 2004, 445, 616–620. 
10. Ozaki S, Zen Y, Inoue M. Biomarker expression in cervical intraepithe-
lial neoplasia: potential progression predictive factors for low-grade 
lesions. Hum Pathol. 2011, 42, 1007–1012. 
11. Riethdorf S, Neffen EF, Cviko A, Loning T, Crum CP, Riethdorf L. p16INK4a 
expression as biomarker for HPV 16–related vulvar neoplasias. Hum 
Pathol. 2004, 35, 1477–1483. 
12. Rokita W, Skawiński D, Zmelonek-Znamirowska A. Wyniki badań cy-
tologicznych i immunocytochemiczna identyfikacja białek p16 i Ki67 
u kobiet ze śródnabłonkową neoplazją i rakiem szyjki macicy. Ginekol 
Pol. 2012, 83, 822–826.
13. Schmidt D, Bergeron C, Denton KJ, Ridder R. p16/ki-67 dual-stain cy-
tology in the triage of ASCUS and LSIL papanicolaou cytology: results 
from the European equivocal or mildly abnormal papanicolaou cytology 
study. Cancer Cytopathol. 2011, 119, 158–166.
14. Singh M, Mockler D, Akalin A, Burke S, Shroyer A, Shroyer KR. Immuno-
cytochemical colocalization of P16(INK4a) and Ki-67 predicts CIN2/3 and 
AIS/adenocarcinoma. Cancer Cytopathol. 2012, 120, 26–34. 
15. Petry KU, Schmidt D, Scherbring S, [et al.]. Triaging Pap cytology negative, 
HPV positive cervical cancer screening results with p16/Ki-67 Dual-sta-
ined cytology. Gynecol Oncol. 2011, 121, 505–509.
16. Nasierowska-Guttmejer A, Górnicka B (ed.). Zalecenia do diagnostyki 
histopatologicznej nowotworów. Centrum Onkologii, Oddział Gliwice, 
Polskie Towarzystwo Patologów, Warszawa 2013.
